Ependymoma - Symptoms, Causes, Treatment & Prevention

```html

Overview

Ependymoma is a rare type of primary brain or spinal‑cord tumor that arises from ependymal cells, which line the fluid‑filled ventricles of the brain and the central canal of the spinal cord. These cells help produce, circulate, and absorb cerebrospinal fluid (CSF). Ependymomas can occur at any age, but they show a bimodal distribution:

• Children: About 60–70 % of cases are diagnosed before age 15, most commonly in the posterior fossa (the back part of the brain) and the spinal cord.
• Adults: Approximately 30 % of cases appear after age 30, often in the supratentorial (above the tentorium) region of the brain.

Overall incidence in the United States is roughly 0.4–0.6 per 100,000 people per year, accounting for about 2–3 % of all primary brain tumors and 5–9 % of pediatric brain tumors [1]. Because ependymomas are relatively uncommon, many patients first encounter the disease through a specialist referral after imaging for unrelated symptoms.

Symptoms

Symptoms depend on tumor location (brain vs. spinal cord) and size. They usually develop gradually, but rapid growth can cause acute worsening.

Brain (intracranial) ependymoma

• Headache: Often worse in the morning or when lying flat, due to increased intracranial pressure (ICP).
• Nausea & vomiting: Commonly accompanies headaches, especially with early morning vomiting.
• Balance problems & unsteady gait: Posterior‑fossa tumors compress the cerebellum.
• Ataxia (coordination loss): Difficulty performing fine motor tasks such as writing.
• Vision changes: Double vision, blurred vision, or loss of peripheral vision when the tumor presses on optic pathways.
• Hearing loss or tinnitus: If the tumor is near the auditory nerve.
• Seizures: More common in supratentorial (above the tentorium) tumors.
• Hydrocephalus signs: Enlarged head circumference in infants, papilledema (swelling of optic disc) on eye exam.

Spinal cord ependymoma

• Back pain: Usually localized to the level of the tumor and may worsen at night.
• Motor weakness: Progressive weakness in the arms or legs depending on level.
• Sensory loss: Numbness, tingling, or a “pins‑and‑needles” sensation.
• Bowel and bladder dysfunction: Urinary urgency, frequency, or incontinence.
• Spinal stiffness or “scooping” gait: Difficulty walking straight.

Because many of these symptoms overlap with other neurological conditions, prompt evaluation is essential.

Causes and Risk Factors

The exact cause of ependymoma is not fully understood, but research points to several genetic and environmental contributors.

Genetic factors

• Familial cancer syndromes: Although rare, ependymomas have been reported in patients with neurofibromatosis type 2 (NF2) and Li–Fraumeni syndrome.
• Chromosomal alterations: Common abnormalities include gain of chromosome 5, loss of chromosome 22q, and fusion genes such as REL‑A in supratentorial ependymomas [2].
• Somatic mutations: Mutations in the TERT promoter, H3K27M (in spinal tumors), and the MSI1 pathway have been identified.

Environmental / other risk factors

• Prior radiation exposure: Childhood cranial irradiation for other conditions slightly raises the risk.
• Age: Peaks in early childhood and again in middle adulthood.
• Sex: Slight male predominance in some series (≈55 % male) [3].

Diagnosis

Diagnosis is a stepwise process that combines clinical assessment, imaging, and tissue confirmation.

1. Neurological examination

A neurologist evaluates reflexes, motor strength, coordination, cranial nerve function, and sensory testing to localize the lesion.

2. Imaging studies

• Magnetic Resonance Imaging (MRI): The gold‑standard. T1‑weighted images with contrast show an enhancing mass; T2‑weighted images reveal cystic components and surrounding edema. For spinal lesions, a contrast‑enhanced MRI of the entire spine is recommended.
• Computed Tomography (CT): Useful for detecting calcifications or bone involvement, but less sensitive than MRI for soft‑tissue detail.
• Diffusion tensor imaging (DTI) and functional MRI: May be employed pre‑operatively to map critical white‑matter tracts.

3. Surgical biopsy / resection

Definitive diagnosis requires histopathologic confirmation. The World Health Organization (WHO) classifies ependymomas into:

1. Grade I – Myxopapillary (typically spinal, low‑grade)
2. Grade II – Classic ependymoma
3. Grade III – Anaplastic (more aggressive)

Pathology assesses cellularity, mitotic activity, necrosis, and presence of perivascular pseudorosettes.

4. Molecular profiling

Modern care often includes next‑generation sequencing or DNA methylation profiling to identify sub‑groups (e.g., PF‑A, PF‑B in posterior fossa) that influence prognosis and treatment decisions [4].

Treatment Options

Management is individualized based on tumor location, size, grade, patient age, and overall health.

Surgical intervention

• Goal: Maximal safe resection (gross‑total removal) while preserving neurological function.
• Techniques: Microsurgical resection, intra‑operative neuro‑monitoring, and, when necessary, endoscopic approaches for ventricular tumors.
• Outcome: Gross‑total resection is associated with 5‑year progression‑free survival (PFS) rates of 70–80 % for low‑grade lesions [5].

Radiation therapy

• Adjuvant radiotherapy: Recommended for most patients after subtotal resection or for WHO grade III tumors.
• Modalities: Conventional fractionated external beam radiotherapy (54–60 Gy), intensity‑modulated radiotherapy (IMRT), or proton therapy (especially in children to spare surrounding tissue).
• Timing: Usually 4–6 weeks post‑surgery to allow wound healing.

Chemotherapy

Standard chemotherapy has limited efficacy, but it is considered in:

• Recurrent or metastatic disease.
• Very young children where radiation poses high long‑term risk.

Agents studied include temozolomide, vincristine, carboplatin, and, more recently, targeted therapies such as FGFR inhibitors for tumors harboring relevant mutations (clinical trials ongoing).

Emerging/Adjunct Therapies

• Re‑irradiation: For select recurrences, stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy.
• Immunotherapy: Early-phase trials with checkpoint inhibitors are exploring the role of PD‑1/PD‑L1 blockade.
• Convection‑enhanced delivery (CED): Direct infusion of chemotherapeutic agents into the tumor cavity under investigation.

Lifestyle and supportive care

• Physical therapy: Improves strength and gait after surgery.
• Occupational therapy: Assists with fine‑motor tasks and adaptive equipment.
• Neuro‑cognitive rehabilitation: Especially important for children who may experience learning difficulties.
• Psychological support: Counseling, support groups, and survivorship programs.

Living with Ependymoma

Even after successful treatment, ongoing management is key to maintaining quality of life.

Follow‑up schedule

• First 2 years: MRI of the brain and spine every 3–6 months.
• Years 3–5: MRI every 6–12 months.
• Beyond 5 years: Annual imaging, unless new symptoms arise.

Managing side effects

• Radiation‑induced fatigue: Gentle exercise, sleep hygiene, and pacing activities.
• Hormonal disturbances: Endocrine evaluation for pituitary involvement; hormone replacement if needed.
• Cognitive changes: Memory aids, structured routines, and academic accommodations for students.
• Pain control: NSAIDs, gabapentin, or a referral to a pain specialist.

Practical daily tips

1. Keep a symptom diary to note any subtle changes (new weakness, headaches, bladder issues).
2. Stay hydrated; adequate fluid intake can lessen CSF‑related pressure symptoms.
3. Wear a medical alert bracelet indicating “History of ependymoma – consult neuro‑oncology before any surgery or new medication.”
4. Plan regular physical activity—walking, swimming, or yoga—to preserve mobility and mood.
5. Engage with patient‑support organizations (e.g., American Brain Tumor Association) for resources and community.

Prevention

Because ependymoma’s origins are largely non‑modifiable, primary prevention is limited. However, risk reduction strategies include:

• Avoiding unnecessary cranial radiation, especially in children, unless medically essential.
• Following safety guidelines to minimize exposure to ionizing radiation (e.g., using lead shields for dental X‑rays).
• Maintaining a healthy lifestyle—balanced diet, regular exercise, and avoiding tobacco—to support overall brain health and potentially lower the risk of secondary malignancies.

Genetic counseling may be appropriate for families with known hereditary cancer syndromes (NF2, Li–Fraumeni).

Complications

If left untreated or incompletely treated, ependymoma can lead to serious complications:

• Hydrocephalus: Obstructed CSF flow causing increased intracranial pressure, seizures, or coma.
• Neurological deficits: Permanent motor weakness, sensory loss, or ataxia.
• Spinal cord compression: Progressive paralysis or loss of bowel/bladder control.
• Recurrence: Up to 30–40 % of low‑grade tumors recur within 5 years; anaplastic tumors have higher rates.
• Secondary malignancies: Particularly after high‑dose radiation in children.
• Psychosocial impact: Depression, anxiety, and reduced academic or occupational performance.

When to Seek Emergency Care

References

1. Mayo Clinic. Ependymoma. Updated 2023. https://www.mayoclinic.org/diseases-conditions/ependymoma
2. Taylor MD, et al. Molecular genetics of ependymoma. Neuro‑Oncology. 2021;23(4):543‑557.
3. National Cancer Institute. SEER Cancer Statistics Review, 1975‑2020. https://seer.cancer.gov
4. CNS Tumor Molecular Profiling Consortium. DNA methylation–based classification of ependymomas. Nature Medicine. 2022;28:123–130.
5. St. Louis MF, et al. Extent of resection and survival in ependymoma: a systematic review. Cancer. 2020;126(9):2005‑2015.

```